FDAsafety guidance72% confidence
FDA TA — VERICIGUAT (ORIG)
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Centessa Pharmaceuticals.
Regulatory Analysis
Application ANDA220221. Sponsor: TORRENT PHARMACEUTICALS LTD. Submission status: TA. Submission type: ORIG. Review priority: STANDARD. Active ingredients: VERICIGUAT.
Supporting Context
- Therapeutic area
- Neurology · Narcolepsy
- Sub-indication
- General
Related signal: Cleminorexton Study for Narcolepsy Type 1 and Type 2 Initiated by Centessa Pharmaceuticals